The use of statins for the treatment of depression in patients with acute coronary syndrome

Translational Psychiatry

Volumn 5, Issue 8, 2015, Pages

  Kim, S W ^a   Bae, K Y ^a   Kim, J M ^a   Shin, I S ^a   Hong, Y J ^a   Ahn, Y ^a   Jeong, M H ^a   Berk, M ^b,c   Yoon, J S ^a  

^a Chonnam National University Medical School   (South Korea)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE MB; ESCITALOPRAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME VARIABLE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPLICATION; DEPRESSIVE DISORDER;

ACUTE CORONARY SYNDROME; CITALOPRAM; COHORT STUDIES; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84994558840     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.116     Document Type: Article

References (41)

1. Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ 1996; 313: 649-651.
2. Park YM, Lee BH, Lee SH. The association between serum lipid levels, suicide ideation, and central serotonergic activity in patients with major depressive disorder. J Affect Disord 2014; 159: 62-65.
3. O'Neil A, Sanna L, Redlich C, Sanderson K, Jacka F, Williams LJ et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012; 10: 154.
4. Parsaik AK, Singh B, Murad MH, Singh K, Mascarenhas SS, Williams MD et al. Statins use and risk of depression: a systematic review and meta-analysis. J Affect Disord 2014; 160: 62-67.
5. Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC, Kotowicz MA et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 2010; 79: 323-325.
6. Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM. Long-term statin use and psychological well-being. J Am Coll Cardiol 2003; 42: 690-697.
7. Ghanizadeh A, Hedayati A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlledclinical trial. Depress Anxiety 2013; 30: 1084-1088.
8. Haghighi M, Khodakarami S, Jahangard L, Ahmadpanah M, Bajoghli H, Holsboer-Trachsler E et al. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder. J Psychiatr Res 2014; 58: 109-114.
9. Anderson G, Berk M, Dean O, Moylan S, Maes M. Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 2014; 28: 1-10.
10. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013; 18: 595-606.
11. Stafford L, Berk M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 2011; 72: 1229-1235.
12. Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, Steffens S et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford) 2009; 48: 233-242.
13. Link A, Ayadhi T, Böhm M, Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006; 27: 2945-2955.
14. Mayer C, Gruber HJ, Landl EM, Pailer S, Scharnagl H, Truschnig-Wilders M et al. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3-and C/EBP-dependent fashion. Int J Clin Pharmacol Ther 2007; 45: 319-327.
15. Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol 2010; 25: 399-405.
16. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. Prog Neurobiol 2009; 88: 64-75.
17. Kim JM, Bae KY, Stewart R, Jung BO, Kang HJ, Kim SW et al. Escitalopram treatment for depressive disorders following acute coronary syndrome: a 24 week double-blind Placebo-controlled trial. J Clin Psychiatry 2015; 76: 62-68.
18. Kim JM, Bae KY, Kang HJ, Kim SW, Shin IS, Hong YJ et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investig 2014; 11: 89-94.
19. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
20. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22-33.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. American Psychiatric Press Inc: Washington, DC, USA, 1994.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
23. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-464.
24. Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012; 46: 549-557.
25. Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O'Neil A et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 2013; 11: 74.
26. Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013; 11: 200.
27. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-741.
28. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014; 29: 216-223.
29. Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a doubleblind, randomized, placebo-controlled trial. J Clin Psychiatry 2014; 75: 628-636.
30. Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES et al. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology 2013; 38: 767-776.
31. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26: 607-611.
32. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346: f288.
33. Jeong BO, Kim SW, Kim SY, Kim JM, Shin IS, Yoon JS. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. Psychosomatics 2014; 55: 213-220.
34. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008; 65: 220-231.
35. Jacka FN, Cherbuin N, Anstey KJ, Butterworth P. Dietary patterns and depressive symptoms over time: examining the relationships with socioeconomic position, health behaviours and cardiovascular risk. PLoS One 2014; 9: e87657.
36. Pasco JA, Williams LJ, Jacka FN, Henry MJ, Coulson CE, Brennan SL et al. Habitual physical activity and the risk for depressive and anxiety disorders among older men and women. Int Psychogeriatr 2011; 23: 292-298.
37. Pasco JA, Williams LJ, Jacka FN, Ng F, Henry MJ, Nicholson GC et al. Tobacco smoking as a risk factor for major depressive disorder: population-based study. Br J Psychiatry 2008; 193: 322-326.
38. Gastelurrutia P, Lupón J, de Antonio M, Urrutia A, Díez C, Coll R et al. Statins in heart failure: the paradox between large randomized clinical trials and real life. Mayo Clin Proc 2012; 87: 555-560.
39. Bonsu KO, Kadirvelu A, Reidpath DD. Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. Syst Rev 2013; 2: 22.
40. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T et al. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 2013; 109: 318-324.
41. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-125.